{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:40:27Z","timestamp":1792294827696,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","award":["A-6119"],"award-info":[{"award-number":["A-6119"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","award":["A-6119"],"award-info":[{"award-number":["A-6119"]}],"id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["20170101"],"award-info":[{"award-number":["20170101"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41587-019-0205-0","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T12:03:06Z","timestamp":1564747386000},"page":"884-894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":238,"title":["A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-0857","authenticated-orcid":false,"given":"Julia F.","family":"Alterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-3333","authenticated-orcid":false,"given":"Bruno M. D. C.","family":"Godinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-6503","authenticated-orcid":false,"given":"Matthew R.","family":"Hassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-1249","authenticated-orcid":false,"given":"Chantal M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reka A.","family":"Haraszti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-9635","authenticated-orcid":false,"given":"Paul","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton A.","family":"Turanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-7001","authenticated-orcid":false,"given":"Gwladys","family":"Gernoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Gray-Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina C.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-9367","authenticated-orcid":false,"given":"Samer M.","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sena-Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athma A.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"DiFiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"205_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"205_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1021\/acs.bioconjchem.5b00265","volume":"26","author":"ME Ostergaard","year":"2015","unstructured":"Ostergaard, M. E. et al. Efficient synthesis and biological evaluation of 5\u2019-galnac conjugated antisense oligonucleotides. Bioconjug. Chem. 26, 1451\u20131455 (2015).","journal-title":"Bioconjug. Chem."},{"key":"205_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cbic.201500023","volume":"16","author":"KG Rajeev","year":"2015","unstructured":"Rajeev, K. G. et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem. 16, 903\u2013908 (2015).","journal-title":"Chembiochem."},{"key":"205_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron. 74, 1031\u20131044 (2012).","journal-title":"Neuron."},{"key":"205_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"205_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819\u2013829 (2013).","journal-title":"N. Engl. J. Med."},{"key":"205_CR7","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1038\/mtna.2015.38","volume":"4","author":"JF Alterman","year":"2015","unstructured":"Alterman, J. F. et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids 4, e266 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"205_CR8","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1038\/mtna.2016.50","volume":"5","author":"M Nikan","year":"2016","unstructured":"Nikan, M. et al. Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids 5, e344 (2016).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"205_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/nat.2018.0725","volume":"28","author":"MF Osborn","year":"2018","unstructured":"Osborn, M. F. & Khvorova, A. Improving small interfering RNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 28, 128\u2013136 (2018).","journal-title":"Nucleic Acid Ther"},{"key":"205_CR10","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1021\/acs.bioconjchem.7b00226","volume":"28","author":"M Nikan","year":"2017","unstructured":"Nikan, M. et al. Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain. Bioconjug. Chem. 28, 1758\u20131766 (2017).","journal-title":"Bioconjug. Chem."},{"key":"205_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/nar\/gkw1005","volume":"45","author":"S Ly","year":"2017","unstructured":"Ly, S. et al. Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res. 45, 15\u201325 (2017).","journal-title":"Nucleic Acids Res."},{"key":"205_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374\u2013387 (2014).","journal-title":"Nucleic Acid Ther."},{"key":"205_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.20140391","volume":"212","author":"U Flierl","year":"2015","unstructured":"Flierl, U. et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J. Exp. Med. 212, 129\u2013137 (2015).","journal-title":"J. Exp. Med."},{"key":"205_CR14","doi-asserted-by":"publisher","first-page":"e0187574","DOI":"10.1371\/journal.pone.0187574","volume":"12","author":"S Sewing","year":"2017","unstructured":"Sewing, S. et al. Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. PLoS ONE 12, e0187574 (2017).","journal-title":"PLoS ONE"},{"key":"205_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"ST Crooke","year":"2017","unstructured":"Crooke, S. T., Wang, S., Vickers, T. A., Shen, W. & Liang, X. H. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 35, 230\u2013237 (2017).","journal-title":"Nat. Biotechnol."},{"key":"205_CR16","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/nar\/gky037","volume":"46","author":"MR Hassler","year":"2018","unstructured":"Hassler, M. R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185\u20132196 (2018).","journal-title":"Nucleic Acids Res."},{"key":"205_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ymthe.2006.01.001","volume":"13","author":"MA Behlke","year":"2006","unstructured":"Behlke, M. A. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644\u2013670 (2006).","journal-title":"Mol. Ther."},{"key":"205_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cmdc.201000156","volume":"5","author":"J Winkler","year":"2010","unstructured":"Winkler, J., Stessl, M., Amartey, J. & Noe, C. R. Off-target effects related to the phosphorothioate modification of nucleic acids. Chem. Med. Chem. 5, 1344\u20131352 (2010).","journal-title":"Chem. Med. Chem."},{"key":"205_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/nar\/gkg147","volume":"31","author":"M Amarzguioui","year":"2003","unstructured":"Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucl. Acids Res. 31, 589\u2013595 (2003).","journal-title":"Nucl. Acids Res."},{"key":"205_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/108729003321629638","volume":"13","author":"J Harborth","year":"2003","unstructured":"Harborth, J. et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucl. Acid Drug Devel. 13, 83\u2013105 (2003).","journal-title":"Antisense Nucl. Acid Drug Devel."},{"key":"205_CR21","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1093\/nar\/gkx818","volume":"45","author":"JK Nair","year":"2017","unstructured":"Nair, J. K. et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 45, 10969\u201310977 (2017).","journal-title":"Nucleic Acids Res."},{"key":"205_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41\u201351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"205_CR23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430\u20131440 (2017).","journal-title":"N. Engl. J. Med."},{"key":"205_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9258(18)33240-X","volume":"258","author":"YC Lee","year":"1983","unstructured":"Lee, Y. C. et al. Binding of synthetic oligosaccharides to the hepatic Gal\/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258, 199\u2013202 (1983).","journal-title":"J. Biol. Chem."},{"key":"205_CR25","unstructured":"Roehl, I., Schuster, M. & Seiffert, S. US Patent 20110201006 A1 (2011)."},{"key":"205_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106\u2013118 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"205_CR27","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1073\/pnas.0600549103","volume":"103","author":"RW Mahley","year":"2006","unstructured":"Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 103, 5644\u20135651 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2008.06.025","volume":"273","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. & Andersen, P. M. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 273, 67\u201369 (2008).","journal-title":"J. Neurol. Sci."},{"key":"205_CR29","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","volume":"24","author":"MC Didiot","year":"2018","unstructured":"Didiot, M. C. et al. Nuclear localization of huntingtin mRNA Is specific to cells of neuronal origin. Cell. Rep. 24, 2553\u20132560 e2555 (2018).","journal-title":"Cell. Rep."},{"key":"205_CR30","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1523\/JNEUROSCI.3753-13.2014","volume":"34","author":"VS Achuta","year":"2014","unstructured":"Achuta, V. S. et al. Tissue plasminogen activator contributes to alterations of neuronal migration and activity-dependent responses in fragile X mice. J. Neurosci. 34, 1916\u20131923 (2014).","journal-title":"J. Neurosci."},{"key":"205_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.neuron.2015.01.008","volume":"85","author":"X Gu","year":"2015","unstructured":"Gu, X. et al. N17 Modifies mutant huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. Neuron 85, 726\u2013741 (2015).","journal-title":"Neuron"},{"key":"205_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","volume":"14","author":"M DiFiglia","year":"1995","unstructured":"DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075\u20131081 (1995).","journal-title":"Neuron"},{"key":"205_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/NEN.0b013e318198d320","volume":"68","author":"ES Herndon","year":"2009","unstructured":"Herndon, E. S. et al. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J. Neuropathol. Exp. Neurol. 68, 250\u2013261 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"205_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/jnr.10655","volume":"73","author":"A Weyer","year":"2003","unstructured":"Weyer, A. & Schilling, K. Developmental and cell type-specific expression of the neuronal marker NeuN in the murine cerebellum. J. Neurosci. Res. 73, 400\u2013409 (2003).","journal-title":"J. Neurosci. Res."},{"key":"205_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.wneu.2015.10.066","volume":"87","author":"RS Takala","year":"2016","unstructured":"Takala, R. S. et al. Glial fibrillary acidic protein and ubiquitin C-Terminal hydrolase-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 87, 8\u201320 (2016).","journal-title":"World Neurosurg."},{"key":"205_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jnr.20354","volume":"79","author":"D Lind","year":"2005","unstructured":"Lind, D., Franken, S., Kappler, J., Jankowski, J. & Schilling, K. Characterization of the neuronal marker NeuN as a multiply phosphorylated antigen with discrete subcellular localization. J. Neurosci. Res. 79, 295\u2013302 (2005).","journal-title":"J. Neurosci. Res."},{"key":"205_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/cercor\/9.6.543","volume":"9","author":"CL Dou","year":"1999","unstructured":"Dou, C. L., Li, S. & Lai, E. Dual role of brain factor-1 in regulating growth and patterning of the cerebral hemispheres. Cereb. Cortex 9, 543\u2013550 (1999).","journal-title":"Cereb. Cortex"},{"key":"205_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02989-4","volume":"9","author":"MM Janas","year":"2018","unstructured":"Janas, M. M. et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat. Commun. 9, 723 (2018).","journal-title":"Nat. Commun."},{"key":"205_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nmeth854","volume":"3","author":"A Birmingham","year":"2006","unstructured":"Birmingham, A. et al. 3\u2019 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199\u2013204 (2006).","journal-title":"Nat. Methods"},{"key":"205_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato, C., Valenza, M. & Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol. Rev. 90, 905\u2013981 (2010).","journal-title":"Physiol. Rev."},{"key":"205_CR41","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"MM Evers","year":"2018","unstructured":"Evers, M. M. et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a huntington\u2019s disease minipig model. Mol. Ther. 26, 2163\u20132177 (2018).","journal-title":"Mol. Ther."},{"key":"205_CR42","doi-asserted-by":"publisher","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci. Transl. Med. 10, eaar3959 (2018).","journal-title":"Sci. Transl. Med."},{"key":"205_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/hum.2017.199","volume":"29","author":"EL Pfister","year":"2018","unstructured":"Pfister, E. L. et al. Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease. Hum. Gene. Ther. 29, 663\u2013673 (2018).","journal-title":"Hum. Gene. Ther."},{"key":"205_CR44","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin, R. et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197\u20131209 (2012).","journal-title":"Brain"},{"key":"205_CR45","doi-asserted-by":"crossref","first-page":"CT.002","DOI":"10.1212\/WNL.90.15_supplement.CT.002","volume":"90","author":"S Tabrizi","year":"2018","unstructured":"Tabrizi, S. et al. Effects of IONIS-HTTRx in patients with early Huntington\u2019s disease, results of the first HTT-lowering drug trial (CT.002). Neurology 90, CT.002 (2018).","journal-title":"Neurology"},{"key":"205_CR46","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1021\/jm200113t","volume":"54","author":"L Bhagat","year":"2011","unstructured":"Bhagat, L. et al. Novel oligonucleotides containing two 3\u2019-ends complementary to target mRNA show optimal gene-silencing activity. J. Med. Chem. 54, 3027\u20133036 (2011).","journal-title":"J. Med. Chem."},{"key":"205_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/btm2.10035","volume":"1","author":"DW Malcolm","year":"2016","unstructured":"Malcolm, D. W., Sorrells, J. E., Van Twisk, D., Thakar, J. & Benoit, D. S. Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis. Bioeng. Transl. Med. 1, 193\u2013206 (2016).","journal-title":"Bioeng. Transl. Med."},{"key":"205_CR48","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359\u20133364 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"205_CR49","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister, E. L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr. Biol. 19, 774\u2013778 (2009).","journal-title":"Curr. Biol."},{"key":"205_CR50","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/j.ymthe.2018.08.005","volume":"26","author":"B Godinho","year":"2018","unstructured":"Godinho, B. et al. Transvascular delivery of hydrophobically modified siRNAs: Gene silencing in the rat brain upon disruption of the blood-brain barrier. Mol. Ther. 26, 2580\u20132591 (2018).","journal-title":"Mol. Ther."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0205-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41587-019-0205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T13:00:20Z","timestamp":1721566820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0205-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1038\/s41587-019-0205-0","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K., J.F.A., M.R.H. and B.M.D.C.G. have filed a patent application for branched oligonucleotides.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}